ATE501730T1 - Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten - Google Patents

Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten

Info

Publication number
ATE501730T1
ATE501730T1 AT02760986T AT02760986T ATE501730T1 AT E501730 T1 ATE501730 T1 AT E501730T1 AT 02760986 T AT02760986 T AT 02760986T AT 02760986 T AT02760986 T AT 02760986T AT E501730 T1 ATE501730 T1 AT E501730T1
Authority
AT
Austria
Prior art keywords
antagonist
treating psoriasis
antibody
il17d29
polypeptide
Prior art date
Application number
AT02760986T
Other languages
English (en)
Inventor
Emma Moore
Kevin Foley
Karen Madden
Yue Yao
Scott Presnell
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE501730T1 publication Critical patent/ATE501730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02760986T 2001-01-25 2002-01-24 Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten ATE501730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26421901P 2001-01-25 2001-01-25
PCT/US2002/002244 WO2002102411A2 (en) 2001-01-25 2002-01-24 Method for treating psoriasis by using an il-17d antagonist

Publications (1)

Publication Number Publication Date
ATE501730T1 true ATE501730T1 (de) 2011-04-15

Family

ID=23005084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760986T ATE501730T1 (de) 2001-01-25 2002-01-24 Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten

Country Status (8)

Country Link
US (2) US20070048318A1 (de)
EP (2) EP1359938B1 (de)
AT (1) ATE501730T1 (de)
AU (1) AU2002326285A1 (de)
CA (1) CA2435151A1 (de)
DE (1) DE60239450D1 (de)
ES (1) ES2360481T3 (de)
WO (1) WO2002102411A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
AU2005241020B2 (en) 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2008058251A1 (en) * 2006-11-08 2008-05-15 Zymogenetics, Inc. Variants and methods of using transforming growth factor beta-9
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610526B2 (en) 1998-03-13 2003-08-26 Inctye Corporation Human E1-like protein
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
US20070256145A1 (en) * 1998-09-17 2007-11-01 Presnell Scott R Mammalian transforming growth factor beta-9
JP2002525056A (ja) 1998-09-17 2002-08-13 ザイモジェネティクス，インコーポレイティド 哺乳類のトランスフォーミング増殖因子β−９
AR022237A1 (es) * 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
WO2001068859A2 (en) * 2000-03-16 2001-09-20 Amgen Inc. Il-17 receptor like molecules and uses thereof
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
PL1871399T3 (pl) * 2005-04-18 2011-09-30 Sc Dicophar Zastosowanie lecytyny jako leku w leczeniu łuszczycy
US9355528B2 (en) 2013-09-17 2016-05-31 Igt Gaming system and method for providing a cascading symbol game with shifting symbols between multiple symbol display position matrices
TWI616792B (zh) 2017-05-03 2018-03-01 友達光電股份有限公司 觸控顯示裝置的製造方法

Also Published As

Publication number Publication date
WO2002102411A3 (en) 2003-09-18
EP1359938A2 (de) 2003-11-12
CA2435151A1 (en) 2002-12-27
ES2360481T3 (es) 2011-06-06
AU2002326285A1 (en) 2003-01-02
EP2366406A1 (de) 2011-09-21
US20070280936A1 (en) 2007-12-06
WO2002102411A2 (en) 2002-12-27
EP1359938B1 (de) 2011-03-16
US20070048318A1 (en) 2007-03-01
DE60239450D1 (de) 2011-04-28

Similar Documents

Publication Publication Date Title
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE459369T1 (de) Verfahren zur behandlung von entzündungen
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE50301171D1 (de) Verfahren zur chargenweise Beschichtung von Sägedraht
EP1409015A4 (de) Verfahren zur behandlung oder vorbeugung von hauterkrangungen unter verwendung von cd2-bindungsagenzien
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
DE602004026253D1 (de) Verfahren zur Herstellung von Stahlbrammen mit ultra-geringem Kohlenstoffgehalt
ATE537173T1 (de) Verfahren zur herstellung von cucurbiturilen
DE69921450D1 (de) Verfahren zur herstellung von behandelter kieselsäure
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
DE60131545D1 (de) Verfahren zur behandlung von reaktiver arthritis oder schleimbeutelentzündung
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE532620T1 (de) Vorrichtung und verfahren zum temperieren von vorformlingen
DE60324901D1 (de) Verfahren zur oberflächenreinigung von verunreinigungen enthaltendem graphit mittels einer nh4f und h2so4 enthaltenden wässrigen lösung
DE60121815D1 (de) System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen
ATE405659T1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne- proteinen
ATE428721T1 (de) Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon
DE60212363D1 (de) Verfahren zur herstellung von verstärktem platinmaterial
DE60234943D1 (de) Verfahren zur herstellung von nitrierstahl

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1359938

Country of ref document: EP